1-[3-(4-Fluorophenyl)-[1,2]thiazolo[4,5-D]pyrimidin-7-YL]piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[3-(4-Fluorophenyl)-[1,2]thiazolo[4,5-D]pyrimidin-7-YL]piperazine
• 英文别名: 3-(4-fluorophenyl)-7-piperazin-1-yl-[1,2]thiazolo[4,5-d]pyrimidine
• 化学式: C₁₅H₁₄FN₅S
• mdl: MFCD03751730
• 分子量: 315.4
• InChiKey: LESURAYUJPQMLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
  申请人：LUNELLA BIOTECH, INC.

  公开号：US10980821B2

  公开（公告）日：2021-04-20

  Tri-phenyl-phosphonium (TPP) is a non-toxic chemical moiety that functionally behaves as a mitochondrial targeting signaling in living cells. TPP-related compounds may be utilized to target mitochondria in cancer stem cells (CSCs), and may be used for treating and/or preventing tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance, as well as for anti-cancer therapies. Various TPP-related compounds validated for oxygen consumption inhibition (OCR), were non-toxic, and had little or no effect on ATP production in normal human fibroblasts. Yet these compounds selectively target adherent “bulk” cancer cells. These compounds also inhibit the propagation of CSCs in suspension. TPP-related compounds provide a novel chemical strategy for effectively targeting both i) “bulk” cancer cells and ii) CSCs, while specifically minimizing or avoiding off-target side-effects in normal cells, among other useful therapies.

  三苯基膦（TPP）是一种无毒化学分子，在活细胞中具有线粒体靶向信号的功能。TPP 相关化合物可用于靶向癌症干细胞（CSCs）中的线粒体，并可用于治疗和/或预防肿瘤复发、转移、耐药性和/或放疗耐药性以及抗癌疗法。经过验证，各种 TPP 相关化合物都具有耗氧抑制（OCR）作用，而且无毒，对正常人成纤维细胞的 ATP 生成几乎没有影响。然而，这些化合物选择性地针对粘附的 "大块 "癌细胞。这些化合物还能抑制悬浮液中癌细胞的繁殖。TPP 相关化合物提供了一种新型化学策略，可有效靶向 i) "大块 "癌细胞和 ii) CSCs，同时有针对性地减少或避免对正常细胞的脱靶副作用，以及其他有用的疗法。
• Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeast
  申请人：LUNELLA BIOTECH, INC.

  公开号：US11364210B2

  公开（公告）日：2022-06-21

  The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.

  本公开涉及线粒体功能抑制剂。公开了筛选线粒体抑制化合物的方法。还描述了使用称为 mitoriboscins 的线粒体抑制剂--具有抗癌和抗生素特性的基于线粒体的治疗化合物--预防或治疗癌症、细菌感染和致病性酵母菌的方法，以及使用线粒体抑制剂提供抗衰老益处的方法。此外，还公开了特定的 mitoriboscin 化合物和 mitoriboscin 组。
• Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
  申请人：LUNELLA BIOTECH, INC.

  公开号：US11311501B2

  公开（公告）日：2022-04-26

  The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.

  本公开涉及线粒体功能抑制剂。公开了筛选线粒体抑制化合物的方法。还描述了使用称为 mitoriboscins 的线粒体抑制剂--具有抗癌和抗生素特性的基于线粒体的治疗化合物--预防或治疗癌症、细菌感染和致病性酵母菌的方法，以及使用线粒体抑制剂提供抗衰老益处的方法。此外，还公开了特定的 mitoriboscin 化合物和 mitoriboscin 组。
• MITORIBOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING CANCER CELLS, BACTERIA AND PATHOGENIC YEAST
  申请人：LUNELLA BIOTECH, INC.

  公开号：US20200060998A1

  公开（公告）日：2020-02-27

  The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.
• TRIPHENYLPHOSPHONIUM-DERIVATIVE COMPOUNDS FOR ERADICATING CANCER STEM CELLS
  申请人：LUNELLA BIOTECH, INC.

  公开号：US20200376008A1

  公开（公告）日：2020-12-03

  Tri-phenyl-phosphonium (TPP) is a non-toxic chemical moiety that functionally behaves as a mitochondrial targeting signaling in living cells. TPP-related compounds may be utilized to target mitochondria in cancer stem cells (CSCs), and may be used for treating and/or preventing tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance, as well as for anti-cancer therapies. Various TPP-related compounds validated for oxygen consumption inhibition (OCR), were non-toxic, and had little or no effect on ATP production in normal human fibroblasts. Yet these compounds selectively target adherent “bulk” cancer cells. These compounds also inhibit the propagation of CSCs in suspension. TPP-related compounds provide a novel chemical strategy for effectively targeting both i) “bulk” cancer cells and ii) CSCs, while specifically minimizing or avoiding off-target side-effects in normal cells, among other useful therapies.